Results 211 to 220 of about 119,519 (336)

Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO‐2b/3 and ALLEGRO‐LT Clinical Studies for Alopecia Areata

The Journal of Dermatology, EarlyView.
ABSTRACT Ritlecitinib is an oral JAK3/TEC family kinase inhibitor approved for individuals aged ≥ 12 years with severe alopecia areata. Here we report interim efficacy and safety results with ritlecitinib up to Month 24 in the Asian subpopulation from the ALLEGRO phase 2b/3 and ALLEGRO‐LT studies.
Rie Ueki, Masato Mizuashi, Kazutoshi Harada, Xingqi Zhang, Wenyu Wu, Wen‐Hung Chung, Ohsang Kwon, Xin Luo, Victoria Basey, Robert Wolk, Nanzhi Shi, Kayo Fujita, Yimeng Shen, Tomohiro Hirose   +13 more
wiley   +1 more source

Association of Venous Thromboembolism Risk with Atopic Dermatitis and Janus Kinase Inhibitors Treatment: A Mendelian Randomization Study. [PDF]

Clin Appl Thromb Hemost
Chen Z, Wang S, Wang Y.
europepmc   +1 more source

Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor [PDF]

, 2007
Akihiro Muto, Mayumi Hori, Yosuke Sasaki, Akari Saitoh, Iho Yasuda, Tadahito Maekawa, Tomoe Uchida, Keiko Asakura, Tomonori Nakazato, Toshio Kaneda, Masahiro Kizaki, Yasuo Ikeda, Tadashi Yoshida   +12 more
openalex   +1 more source

Pharmacokinetics of Ilunocitinib, a New Janus Kinase Inhibitor, in Dogs. [PDF]

J Vet Pharmacol Ther
Boerngen K, Patel Y, Pittorino M, Toutain CE.   +3 more
europepmc   +1 more source

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel, Peter Foley, Kathryn A. Gibson, Anita Townsend, Gabrielle Louise Reppen, William Romero Gallardo   +5 more
wiley   +1 more source

Janus kinase inhibitors: another potential for uveitis treatment? [PDF]

Ann Eye Sci
Emami S, Kaisari E, Janetos TM.
europepmc   +1 more source

THU0193 Reestablishment of efficacy of tofacitinib, an oral janus kinase inhibitor, in rheumatoid arthritis patients after temporary discontinuation [PDF]

, 2017
Jeffrey Kaine, John Tesser, Ryan DeMasi, Liza Takiya, L Wang, M.R. Snyder, Hongyan Fan, J. Wollenhaupt   +7 more
openalex   +1 more source

Club Cells in Nasal Epithelial Repair: Insights From an IL‐13‐Induced Inflammatory Model

Allergy, EarlyView.
Four inflammatory endotypes of CRSwNP, defined by eosinophil and neutrophil infiltration, show distinct patterns of basal, club, ciliated, and goblet cell expression in nasal epithelium. Using an ALI‐HNECs model, we demonstrate that IL‐13 impairs mucociliary function by promoting club‐to‐goblet cell differentiation while inhibiting club‐to‐ciliated ...
Zhi‐Qun Huang, Jing Liu, Jing Ye, Li‐Ying Sun, Hsiao Hui Ong, Yang Peng, Bing‐Qi Lin, Jun‐Hao Tu, Ke‐Shuang Wang, Yi‐Shan Xiong, Qing Luo, Mark Thong, Yu Xu, De‐Yun Wang   +13 more
wiley   +1 more source

Systemic Inflammation Marker Alterations in Severe Alopecia Areata Patients Treated with Janus Kinase Inhibitors. [PDF]

J Clin Med
Sahin G, Aydin F, Pancar Yuksel E.
europepmc   +1 more source

Pharmacological inhibition of the Janus Kinases enhances ASCL1 protein stability and transcriptional activity [PDF]

Maya A. Hanspal, Jeremy Presland, Kirill Shkura, Marielza Veiga, Sébastien Gillotin   +4 more
openalex   +1 more source